Diabetes Treatment
Sitagliptin may offer best hope for type 2 diabetes patients
Published in Obesity and Diabetes Week, October 3rd, 2005
There are currently more than 194 million people with diabetes worldwide and this figure could exceed 333 million by 2025 if untreated. Current treatments for type 2 diabetes are often limited by their side effect profile, route of administration or difficulties in sustaining glucose control. As a result, there is a need for better tolerated treatments that do not cause weight gain and produce less risk of hypoglycemia for patients with type 2 diabetes.
The results of the two Phase II studies indicate that sitagliptin, an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Epidemiology
Incidence of type 2 diabetes increasing in children in Tokyo - Diabetes Therapy
(Pro3)GIP improves glucose tolerance and reduces insulin resistance - Diabetes Therapy
Beta3 -adrenoceptor agonist increases plasma adiponectin levels - Obesity Pathogenesis
Suppressed skeletal muscle thermogenesis plays role in weight change - Obesity Risk Factors
Variants of ENPP1 are associated with childhood and adult obesity - Age-Related Macular Degeneration
Patent issued in relation to squalamine and other aminosterols - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
